Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4–targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans
This human dosimetry assessment of [⁶⁸Ga]Ga-FZ-NR-1 showed a total body effective dose of approximately 2.00 × 10⁻² mSv/MBq, similar to other <sup>68</sup>Gallium-labeled tracers. Organ absorbed doses were well within the accepted limits, suggesting a favorable radiation risk profile for clinical application as a PET imaging agent targeting Nectin-4. Initial clinical imaging results demonstrates that [⁶⁸Ga]Ga-FZ-NR-1 provides clear visualization of both primary tumors and metastases with high Nectin-4 expression levels.
Authors
- N. Zhang
- Xiaoping Xu (ORCID: https://orcid.org/0009-0001-9971-2395)
- Ming Qi
- Zhihao Chen (ORCID: https://orcid.org/0000-0003-4330-0049)
- Shaoli Song
- Meng Xiao (ORCID: https://orcid.org/0000-0003-2103-7008)
- Xianglin Shi (ORCID: https://orcid.org/0000-0001-9512-7570)
- Hongxing Yang (ORCID: https://orcid.org/0000-0001-5117-5394)
- Haoyao Guo
- Wen Chen
- Jianping Zhang
- Chunjuan Jiang
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- United Imaging Healthcare (China) (CN)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2026-01-04
- DOI
- https://doi.org/10.1186/s13550-025-01361-0
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00